Band-Aid, Tylenol Parent Kenvue Reports Healthy Full-Year Guidance

Kenvue (KVUE) shares surged successful intraday trading Tuesday aft nan institution affirmed its full-year guidance that topped analysts' expectations.

The Tylenol and Band-Aid parent, formerly nan user healthcare portion of Johnson & Johnson (JNJ), continues to expect 2024 nett income maturation betwixt 1% and 3%, pinch nan midpoint good supra analysts' expectations of 1.4%, per Visible Alpha.

"We are connected way to present nan financial targets we group for 2024, and while we are successful nan early days, our activity to toggle shape Kenvue into a bolder, much agile statement focused connected profitable maturation is producing results," Chief Executive Officer (CEO) Thibaut Mongon said. 

Q2 Revenue Beats Estimates, EPS Misses

In nan 2nd quarter, nan institution posted earnings per stock (EPS) of 3 cents connected gross of $4 billion. Analysts had called for EPS of 24 cents connected gross of $3.93 billion. Adjusted EPS of 32 cents topped estimates.

Shares of Kenvue jumped 12% to $20.40 arsenic of 1:40 p.m. ET Tuesday but stay 5% little this year.